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a b s t r a c t
Antibody-dependent enhancement (ADE) of infection may cause severe illness in patients suffering a
secondary infection by a heterologous dengue virus (DENV) serotype. During ADE of infection, cross-
reactive non- or poorly-neutralizing antibodies form infectious virus-Ab complexes with the newly
infecting serotype and enhance virus infection by binding to the Fcγ receptors (FcγR) on FcγR-bearing
cells. In this study, we determined that molecular determinants of DENV2 envelope protein critical for
virus entry during non-ADE infection are also required for ADE infection mediated by FcγRIIA, and
binding of virus-Ab complexes with FcγRIIA alone is not sufﬁcient for ADE of infection. The FcγRIIA
mainly plays an auxiliary role in concentrating the virus–Ab complex to the cell surface, and other
primary cellular receptors are required for virus entry. Understanding the viral entry pathway in ADE of
DENV infection will greatly facilitate rational designs of anti-viral therapeutics against severe dengue
disease associated with ADE.
Published by Elsevier Inc.
Introduction
The dengue virus (DENV) serocomplex consists of 4 distinct
serotypes, DENV1–4, that are members of genus Flavivirus in the
family Flaviviridae. They are the most important mosquito-borne
viral human pathogens, and are transmitted primarily by Aedes
aegypti. A recent study estimated that 390 million human DENV
infections occur annually and 96 million apparent illnesses occurred
in 2010 alone (Bhatt et al., 2013). All four DENV serotypes can cause
dengue fever (DF) and the more severe form, dengue hemorrhagic
fever (DHF). Primary infection in patients older than one year of age
usually results in asymptomatic or self-limited DF, and lifelong
immunity against the infecting serotype (Halstead, 1970). However,
long-term protection is not elicited against infections by other
serotypes (heterologous DENV infections) (Halstead, 1988). Hetero-
logous DENV infection of adults, or infants who have passively
acquired DENV immunity from the mother, are at risk for severe
dengue (Kliks et al., 1988). Many in vitro and in vivo experimental
studies support antibody-dependent enhancement (ADE) of DENV
infection as one of the leading causes of the severe dengue illness
during secondary heterologous infection of humans (Balsitis et al.,
2010; Halstead et al., 2002, 1970; Halstead and O'Rourke, 1977;
Kliks et al., 1988; Kouri et al., 1989; Sabin, 1952).
The DEN virion contains an 11-kb single-stranded, positive-sense
RNA genome encoding three structural and seven non-structural
proteins. The viral nucleocapsid, consisting of capsid (C) proteins
complexed with the viral RNA genome, is surrounded by the viral
envelope derived from cellular membranes containing viral mem-
brane (M) and envelope (E) transmembrane proteins. The DENV E
glycoprotein is responsible for host cell attachment and virus-
mediated cell membrane fusion during virus entry. Several ﬂaviviral
E protein crystal structures have been solved and showed that the E
monomer is composed of 3 discontinuous β-barrel domains (Modis
et al., 2003, 2004, 2005; Rey et al., 1995) designated domain I (DI),
II (DII) and III (DIII), and 180 E monomers are arranged into 90 head-
to-tail homodimers on the surface of each virion (Kuhn et al., 2002).
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The DIII is believed to be responsible for cell attachment, as it has
an immunoglobulin-like structure, which is a common structure
of cell-adhesion proteins. Furthermore, this domain is recognized
by strongly neutralizing monoclonal antibodies (MAbs) that
block virus attachment to cells, and soluble recombinant DIII
has been shown to block virus infection in vitro (Crill and Roehrig,
2001; Hiramatsu et al., 1996; Roehrig et al., 1998; Sukupolvi-Petty
et al., 2007).
Previous studies have demonstrated that ﬂaviviruses enter cells
mainly via receptor-mediated clathrin-dependent endocytosis
(Chu and Ng, 2004; van der Schaar et al., 2008). The E protein
on virion surfaces attaches to extracellular matrix or plasma
membrane receptors such as sulfated glycosaminoglycans (Chen
et al., 1997), DC-SIGN (Navarro-Sanchez et al., 2003; Pokidysheva
et al., 2006), and/or other unidentiﬁed cell surface molecules. The
cell-attached virion is then localized to clathrin-coated pits and
transported into endosomes. Once the endosome is acidiﬁed, the
molecular hinge at the junction of DI and DII triggers a conforma-
tional rearrangement of E proteins from homodimers to homo-
trimers on the virion surface and a co-localization of the fusion
loops in DII of the homotrimers. The homotrimer fusion loops then
insert into the endosomal membrane, resulting in viral-endosomal
membrane fusion, release of viral nucleocapsid, and initiation of
viral replication (Modis et al., 2004).
Although the early events in non-ADE DENV infection have
been studied in vitro, the entry pathway of antibody-coated
virus and the molecular basis of ADE of DENV infection have not
been determined. It is believed that pre-existing non- or sub-
neutralizing levels of cross-reactive antibodies (Abs) raised during
a previous DENV infection bind to the newly infecting hetero-
logous serotype virus, enhancing infection of FcγR-bearing mye-
loid cells such as monocytes and macrophages. Association of the
DENV–Ab complex with FcγR on these cells leads to an increased
number of infected cells (extrinsic ADE) as well as suppression of
innate immunity, resulting in enhanced virus output by infected
cells (intrinsic ADE) (Halstead et al., 2010). In vitro studies have
demonstrated that both FcγRIA and FcγRIIA can mediate enhanced
DENV infection (Kontny et al., 1988; Littaua et al., 1990, Mady et al.,
1991); however, these receptors appeared to utilize different
DENV–Ab internalization mechanisms. The infectivity of immune
complexes is greater upon binding to FcγRIIA than to FcγRIA
(Rodrigo et al., 2006, 2009). The DENV–Ab entry mechanism via
FcγR binding is still unknown, but there are at least two possible
entry models: (1) the Ab-opsonized DENV may directly internalize
into cells by phagocytosis after binding to the FcγR; or (2) the FcγR
may play a role in concentrating DENV–Ab complexes on the cell
surface, but interaction with other cellular receptors is still
required for successful complex internalization and infection
(Mady et al., 1991). Following internalization of the DENV–Ab
complex via FcγR-binding, it is not clear whether viral E protein-
mediated membrane fusion similar to that in the non-ADE DENV
entry pathway is also required to release viral nucleocapsid for
replication.
In this study, we used several DENV2 E protein mutants to
identify molecular determinants critical for virus-immune com-
plex entry via ADE of DENV infection of FcγRIIA-bearing human
myelogenous K562 cells and monkey CV-1 ﬁbroblasts constitu-
tively expressing transfected human FcγRIIA. Previously we used
these mutants to identify critical determinants in the early events
of non-ADE virus entry into several cell lines (Butrapet et al., 2011;
Erb et al., 2010; Huang et al., 2010; Roehrig et al., 2013). Mutants
included in this study bear mutations at critical motifs involved in
receptor binding or virus-mediated membrane fusion during non-
ADE infection by DENV2. Through identiﬁcation of the DENV E
protein determinants for both types of infection, we further
elucidated the virus–Ab complex entry mechanism.
Results
Optimization of the in vitro ADE assay
All ADE assays in this study were conducted with the same lot
of MAb 4G2. The MAb was serially diluted to determine its optimal
concentration for ADE of wild-type (WT) DENV2 infection in K562
cells at 3 different MOIs, and enhancement of infection was
measured by increased vRNA production (Fig. 1A). At both MOIs
of 1 and 0.2, enhancement (at least 2-fold higher vRNA than that of
non-ADE infection control) was achieved at 1:2000–1:4000 dilu-
tions of MAb 4G2. At MOI of 0.01, the enhancement was observed
between 1:4000 and 1:20,000 dilutions. Although 1:40,000 dilu-
tion also resulted in 2-fold higher mean titer than the non-ADE
virus infection control, it was excluded due to its higher standard
deviation. Based on the titration results, 1:4000 dilution of 4G2
was selected for optimization of the ADE assay using Fluorescence-
Activated Cell Scanning (FACS) analysis to measure enhancement
of cell infection rates. Cells infected by WT DENV2 at different
MOIs (0.01, 0.1, 0.5, and 1.0) pre-incubated with 4G2 at 1:4000
dilution showed obvious ADE as measured by FACS analysis of
virus-infected cells, and Fig. 1B shows the results with MOI¼0.5 as
a representative example.
Although 1:4000 dilution of 4G2 was found to result in
consistent enhancement effect at a wide range of MOI, the peak
enhancement day was delayed in the cells infected with lower
MOIs. The peak enhancement days of infection (measured by
FACS) with WT DENV2 at MOI of 0.5, 0.1 and 0.01 were days 2,
3 and 4 post infection (pi), respectively, and the enhancement
effect became undistinguishable from the non-ADE infection
rapidly after the peak day. This is expected, as the enhancing
MAb was only present in the initial virus–Ab infection of the cells
and subsequent virus infection cycles in the culture were in non-
ADE conditions, thereby the initial enhancement effect was
eventually masked by the later non-ADE cycles. Due to the time-
dependent nature of the assay, it was ideal to conduct the ADE
assay at high MOI and analyze samples as soon as the viral
antigens in the infected cells reached the FACS detectable level.
Therefore, we conducted most of the following experiments at
MOI¼0.5. However, two of the DENV2 mutants in the study are
replication-defective and cannot yield sufﬁcient titers to support
such high MOI. Therefore, lower MOIs (0.01 or 0.1) were used for
experiments with those mutants. To compensate for the slower
replication characteristics of all tested DENV2 mutants, we
extended our assays for 1 to 2 additional days after the WT-ADE
peak day to ensure detection of potentially delayed enhancement
kinetics. In addition, WT DENV2 was included as the positive ADE
control in every experiment at the sameMOI as eachmutant to ensure
all the experimental conditions could successfully detect ADE.
To conﬁrm that the enhanced infection was Ab-dependent, we
used a 4G2-epitope knockout mutant, G106L, in the ADE assay.
Mutant G106L was engineered with a G–L substitution at AA 106
within the fusion loop (Huang et al., 2010). Although this mutant is
fusion-competent and infectious, it has lost the capacity to bind to
4G2. Unlike the 4G2-opsonized WT virus, pre-incubation of
mutant G106L with 4G2 did not result in enhancement of cell
infection between 2 and 4 days pi (Fig. 1C), conﬁrming that
enhanced infection requires binding of 4G2 to DENV2.
The lysine 305, 307 and 310 cluster but not the FG loop on DIII is
critical for both ADE and non-ADE infections of K562 cells
Two E DIII mutant DENV2, VEPGΔ and KKK305/307/310EEE,
bearing deletions or substitutions at putative receptor binding
sites (Erb et al., 2010; Roehrig et al., 2013) were chosen for this
study (Table 1 and Fig. 2). The VEPGΔ mutant has a deletion of the
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FG loop (AA 382-385) between strands F and G on the lateral ridge
of DIII. We infected K562 cells with mutant VEPGΔ or WT DENV2
at MOI of 0.5 with or without enhancing 4G2 pre-incubation
(Fig. 3A). Results showed that without 4G2, the proportion of
mutant VEPGΔ-infected cells was similar to that of WT virus-
infected cells on day 2 pi, but the mutant showed a somewhat
lower infection rate than the WT virus by day 3 pi. This result was
consistent with our previous observation that deletion of the
FG loop impaired virus replication efﬁciency in mammalian cells
(Erb et al., 2010). When mutant VEPGΔ was opsonized with
enhancing 4G2, a signiﬁcant increase in infected cells compared
to non-ADE infections was observed on both days 2 and 3. This
positive ADE effect was also conﬁrmed by measuring the extra-
cellular vRNA levels by qRT-PCR (data not shown).
Table 1
Characteristics of WT DENV2 and E protein mutants.
DENV2 Mutations Peak titer (log10 TCID50/ml)a TSb MAb 4G2 bindingc References
Location Predicted function C6/36 Vero K562
30P-NBX (WT, 16681) na na 9.63 7.38 7  þ Huang et al., 2010
VEPGΔ DIII-FG loop Receptor binding 8.5 4.5 4.88  þ Erb et al., 2010
KKK305/307/310EEE DIII-A strand Receptor binding 7.25 Lethal Lethal  þ Roehrig et al., 2013
G104S DII-cd loop Membrane fusion 8.63 2.5 Lethal þ þ Huang et al., 2010
G106L DII-cd loop Membrane fusion 7.88 5.36 5.5   Huang et al., 2010
L135G DII-eE0 loop Molecular hinge 7 Lethal Lethal þ þ Butrapet et al., 2011
a Peak titer following infection at MOI of 0.001. Lethal: no detectable viable virus. Culture temperature: C6/36 cells at 28 1C, Vero and K562 cells at 37 1C.
b TS: Temperature sensitive; TS mutant viruses were able to replicate efﬁciently in Vero cells at 28 1C, but not at 37 1C.
c MAb 4G2 reactivity measured by immunoﬂuorescence assay with virus-infected C6/36 cells.
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Fig. 1. ADE assay in K562 cells. (A) Titrations of MAb 4G2 for ADE of infection in K562 cells. Quantitation of vRNA in medium of cells infected with WT DENV2 pre-incubated
with serial dilutions of 4G2 by qRT-PCR. Samples were collected and measured from day 2 (MOI¼0.2 and 1.0) or 3 (MOI¼0.01) pi. Dotted line shows the cutoff of qRT-PCR.
(B) FACS dot plot analysis of ADE assay with WT DENV2 (MOI¼0.5). Infected K562 cells were harvested and stained with anti-M protein 2H2-AlexaFluor-488 on day 2 pi.
Numbers indicate percentages of infected cells. (C) Veriﬁcation of ADE assay. DENV2 WT virus and mutant G106L were used in the assay. Percentages of K562 cells infected
with virus-4G2 complex or virus without 4G2 were measured by FACS on days 2–4 pi. Signiﬁcant difference (*po0.05) between cell infection rates with and without 4G2 of
each virus were used to indicate positive enhancement.
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Mutant KKK305/307/310EEE, bearing K to E substitutions at
residues 305, 307, and 310 on the A strand of DIII, is infectious in
mosquito C6/36 cells but not in Vero cells (Table 1) (Roehrig et al.,
2013). In this study, we found that this triple mutant did not grow
in K562 cells in the absence of 4G2, and 4G2-opsonization of the
mutant failed to rescue infectivity (Fig. 3B). The results were also
KKK305/307/310VPEG(382-384)
DII
DI
DIII
G104L135
Fig. 2. Location of mutations introduced into DENV2 E protein. (A) Top-view of E homodimer on mature virion was acquired from Protein Data Bank [PDB ID: 1OAN] and
rendered by Polyview-3D (Porollo and Meller, 2007). E protein domains I, II and III are shown in red, yellow and blue, respectively. The glycan chains are not shown. Locations
of mutated AA residues are highlighted on WT DENV2 E protein as well as shown in the zoom-in images. Putative receptor-binding residues targeted for mutation, FG
loop (382–385 VEPG), shown in magenta, and KKK305/307/310, shown in green. Residues targeted for fusion-defective mutations, G104S and L135G, are shown in cyan.
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DENV2 at MOI¼0.5. (B) Infection rates of mutant KKK305/307/310EEE or WT DENV at MOI¼0.01. Signiﬁcant difference (*po0.05) between cell infection rates of each virus
with and without 4G2 were used to indicate positive enhancement.
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conﬁrmed by the lack of increase in extracellular vRNA levels
during the 5-day infection period (data not shown). Because the
triple mutations may have signiﬁcantly altered the E protein
structure, this could potentially affect nearby or even distant Ab
epitopes, such as the 4G2 epitope. To conﬁrm that the failure of
4G2-ADE infection was not due to the loss of 4G2 binding capacity
of this mutant, we conducted an immunoﬂuorescence assay (IFA)
of virus-infected C6/36 cells with 2-fold serial dilutions of 4G2.
The results demonstrated that both mutant KKK305/307/310EEE
and WT DENV2 infected cells bound the MAb to similar titration
endpoints, suggesting that the triple mutant E protein retained
similar 4G2-binding capacity to the WT DENV2 (Table 1).
Using C6/36 cells in a neutralization assay, we also conﬁrmed that
4G2 can effectively neutralize both WT and the triple mutant
viruses (data not shown), suggesting the binding between 4G2 and
triple mutant was fully functional.
Virus-mediated membrane fusion is required for ADE infection
of K562 cells
Two temperature-sensitive fusion-defective mutants, G104S and
L135G (Table 1 and Fig. 2), were investigated to determine whether
ADE infection requires competent viral fusion activity. The G104S
mutation resides within the cd loop of DII that is known to be the
fusion loop. The L135G mutation occurs in the E0 loop (hinge-2
peptide) that is part of the molecular hinge between DI and DII.
These two mutants were fusion-defective and not infectious in Vero
cells at 37 1C, but became infectious at 28 1C (Huang et al., 2010;
Butrapet et al., 2011). As expected, we observed that both mutants
were also temperature-sensitive in K562 cells; they did not repli-
cate in the cells at 37 1C, but grew as well as WT DENV2 in K526
cells at 28 1C (Fig. 4). The temperature-sensitivities of these mutants
were reversible, since pre-incubation of the mutants at 37 1C (with
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or without 4G2) did not block subsequent viral replication after
culture temperatures were lowered to 28 1C (Fig. 4C and E). This
property allowed us to study the mutants under both fusion-
defective and -competent conditions.
Opsonization of the mutants with 4G2 did not enhance or
rescue their infectivity at 37 1C (Fig. 4A and D), but both 4G2-
opsonized mutants exhibited ADE similar to opsonized WT DENV2
when infected cells were cultured at 28 1C (Fig. 4B and E).
Previously, we have veriﬁed that both G104S and L135G retained
similar 4G2-binding capacity as WT DENV2 when tested by IFA
with viral antigens expressed in C6/36 cells cultured at 28 1C
(Table 1). Interestingly, ADE of G104S infection in K562 cells at
28 1C was not observed if pre-incubation of G104S with 4G2 was
conducted at 37 1C (Fig. 4C), suggesting that G104S failed to form a
complex with 4G2 at 37 1C. It has been demonstrated that the
conformation of dengue virions differs at 37 1C and 28 1C
(Fibriansah et al., 2013; Zhang et al., 2013). The 4G2 epitope is
located close to the fusion loop, and the G104S mutation in the
fusion loop likely disrupted the epitope conformation required for
effective 4G2 binding at 37 1C. On the other hand, mutant L135G
pre-incubated with 4G2 at 37 1C showed successful infection
enhancement after the temperature was shifted to 28 1C post cell
infection (Fig. 4E). All the ADE assay results in Fig. 4 have also been
conﬁrmed with qRT-PCR of vRNA output (data not shown).
ADE of infection is not observed in CV-1 CD-32 cells
To further investigate whether expression of FcγRIIA alone
sufﬁced for ADE infection, we also performed the in vitro ADE
assay with WT DENV2 in the stable FcγRIIA-expressing CV-1
CD-32 cell line. This cell line was previously used to demonstrate
that FcγRIIA can modulate neutralization of DENV–Ab complex
infectivity (Rodrigo et al., 2009). Despite multiple efforts and
testing various MAbs (4G2, 3H5, and 1A1D-2) that showed good
enhancement of WT DENV2 infection in K562 cells, we were not
able to detect any ADE of WT DENV2 infection in the CV-1 CD32
cells (data not shown). Instead, virus neutralization was demon-
strated at all dilutions of the MAbs. We observed that the CV-1
CD32 cell infection rate by the WT virus without Ab was sig-
niﬁcantly lower than that typically observed in WT virus-infected
K562 cells at 2 days pi. To further conﬁrm this observation,
we conducted three separate experiments, with 2 or 3 replicates
in each experiment, to directly compare WT DENV2 infectivity in
K562 and CV-1 CD32 cells at MOI of 0.5 without enhancing
Ab (Table 2). The results revealed that the CV-1 CD32 cells are
signiﬁcantly less susceptible (po0.05) to DENV2 infection than
K562 cells.
To investigate whether variations in the level of FcγRIIA
expression on K562 and CV-1 CD-32 cells might contribute to
the differences in ADE infection, we stained FcγRIIA molecules on
both cell types with anti-CD32-PE and measured the PE intensity
by FACS. The Geometric Mean Fluorescence Intensity (GMFI) of
stained FcγRIIA and the percentage of cells expressing FcγRIIA
were compared. The results showed that both cell lines exhibited
a similar proportion of cells expressing FcγRIIA, but K562 cells
expressed signiﬁcantly less FcγRIIA (lower GMFI) than CV-1 CD32
cells (Table 2). This observation suggested that the lack of ADE
of DENV2 infection in CV-1 CD32 cells was not due to insufﬁcient
expression of FcγRIIA on the cell surface.
Discussion
Viral attachment and virus-mediated endosomal membrane
fusion are two critical early events in the DENV entry pathway.
Our previous mutagenesis studies in the DENV2 E protein have
identiﬁed several functional motifs involved in these events
(Butrapet et al., 2011; Erb et al., 2010; Huang et al., 2010;
Roehrig et al., 2013). In this study, for the ﬁrst time to our
knowledge, we have identiﬁed molecular determinants on the
DENV2 E protein that are critical for virus entry during ADE
infection of FcγRIIA-expressing cells by virus–Ab complexes.
Methods for inducing and assaying ADE of infection were
optimized in a constitutively FcγRIIA-expressing K562 cell line
using ﬂavivirus group cross-reactive MAb 4G2. Using mutant
G106L, which lacks the epitope recognized by 4G2, we conﬁrmed
the enhancement effect observed in the ADE assay was Ab-
dependent. We expected that a lower virus MOI would require
greater dilutions of Ab to maintain the correct ratio between virus
and Ab for ADE. Indeed, the dilution range of 4G2 capable of
mediating ADE of DENV2 infection at MOI of 0.01 was somewhat
higher than that for higher MOIs. However, we found that the
same 1:4000 dilution of 4G2 can effectively induce ADE of WT
DENV2 infection at all the various MOIs (0.01–1.0) we tested
(Figs.1, 3, and 4).
The FG loop of E DIII has long been proposed to be a major
receptor-binding domain for mosquito cells, because it is unique
for mosquito-borne ﬂaviviruses (Rey et al., 1995) and recognized
by several strongly-neutralizing Abs (Gromowski and Barrett,
2007; Hiramatsu et al., 1996). VEPG is the serotype-speciﬁc AA
sequence of the FG loop for DENV2. Using mutant VEPGΔ virus, we
previously demonstrated that the FG loop is dispensable for
infection of C6/36 cells, but important for effective viral midgut
infection and dissemination in Ae. aegypti mosquitoes (Erb et al.,
2010). We also showed that deletion of the FG loop only reduced
viral replication efﬁciency and genetic stability in Vero cells. In this
study, we further determined that the FG loop was not required for
either ADE or non-ADE infection in K562 cells.
The KKK305/307/310EEE mutation was shown to be lethal in
mammalian cells, including Vero, HepG2, and K562 cells, and the
mutant virus had lower infectivity than WT virus for C6/36 cells
(Roehrig et al., 2013). In the current study using FACS analysis, we
could not detect nascent prM protein synthesis by MAb 2H2
staining of the infected K562 cells 3–5 days pi (Fig. 3B), suggesting
that blockage of the mutant infection occurred before viral poly-
protein translation and processing. Because the triple mutant was
found to be fusion competent (Huang et al., 2010), the blockage
likely occurred before membrane fusion. This mutant virus was
also shown to lose reactivity with several MAbs that block
attachment of DENV2 to Vero cells (Roehrig et al., 2013); therefore,
the triple K motif is likely critical for DENV2 attachment to
mammalian cells during non-ADE infection. Since the mutant
virus opsonized with enhancing 4G2 was able to attach to K562
cells via FcγRIIA binding, it may overcome its infectivity blockage if
the binding leads to direct cell entry by the virus–Ab complex. Our
results indicated, however, that 4G2-opsonization of the mutant
was not sufﬁcient to bypass the viral attachment defect caused by
these triple mutations. Similarly, our previous study also showed
that the N67-glycan on the E protein of the triple mutant virus
was intact, but the interaction between the glycan and DC-SIGN,
Table 2
Susceptibility to WT DENV2 infection and FcγRIIA expression levels on K562 and
CV-1 CD32 cells.
K562 CV-1 CD32
Susceptibility to WT DENV2a 7.7670.97% 3.6671.07%
Cells expressing FcγRIIA 60.2677.22% 66.3278.06%
GMFI of FcγRIIA on cells 55.57711.14 86.39714.90
a Percentage of cells infected with DENV2 (MOI¼0.5) without MAb on day 2 pi.
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another important cell surface receptor involved in DENV entry of
dendritic cells and macrophages, expressed on DC-SIGN-
transformed Raji cells was not sufﬁcient to rescue the defect of
the triple K mutations (Roehrig et al., 2013). Taken together, these
results indicated that attachment to other, undeﬁned cellular
receptors engaging the triple K motif is essential for DENV2 ADE
and non-ADE infection in many mammalian cells.
The ability of DENV to escape the endosome and release its
nucleocapsid into the cytoplasm for replication prior to lysosomal
degradation is critical during virus entry via clathrin-mediated
endocytosis in non-ADE infection. During ADE of DENV infection,
virus–Ab complexes binding to FcγR may permit the virus–Ab to
enter cells through phagocytosis. Because virions that enter by
FcγR-mediated phagocytosis would also eventually enter the
endosomal/lysosomal pathway, viral–endosomal membrane
fusion is likely necessary for the infectivity of virus–Ab complexes
that enter through phagocytosis (reviewed in Flannagan et al.,
2012; Smit et al., 2011). Indeed, using 2 temperature-sensitive
fusion mutant viruses (G104S and L135G) with mutations targeted
to affect different steps in fusion, we demonstrated that viral E
protein conformation-mediated membrane fusion is critical for
infectivity under both ADE and non-ADE conditions.
The CV-1 CD32 cells were previously shown to exhibit lower
neutralization kinetics for DENV2 (required higher Ab amount to
neutralize the virus) when compared to CV-1 control cells (CV-1
cells transfected with empty vector) (Rodrigo et al., 2009). We
observed similar results when comparing the neutralization of WT
DENV2 by 4G2 in CV-1 CD32 cells and in CV-1 control cells (data
not shown). Clearly the interaction between DENV–Ab complexes
and the FcγRIIA on CV-1 CD32 cells can slightly augment the
infectivity of opsonized DENV, resulting in lower neutralization
kinetics. However, ADE of WT DENV2 infection was not observed in
CV-1 CD32 cells with any of the MAbs tested, and this was not due
to insufﬁcient expression of FcγRIIA on the CV-1 CD32 cells. The
CV-1 CD-32 cells were less susceptible than K562 cells to WT
DENV2 infection under non-ADE conditions, indicating that CV-1
cells may possess signiﬁcantly fewer primary DENV2 receptors than
the K562 cells. This result suggested that without sufﬁcient primary
receptors, FcγRIIA alone was not enough to mediate detectable ADE
of DENV2 infection in CV-1 CD-32 cells. Taken together, our results
from both K562 and CV-1 CD-32 cells indicated that FcγRIIA may
only play an auxiliary role in concentrating DENV to the cell surface,
and other primary DENV2 receptors may be required for effective
virus internalization during ADE of infection.
Functional domains on the E protein of DENV required for non-
ADE infection have been actively studied, but their involvement
in ADE of DENV infection has not been directly addressed. Such
knowledge is important for development of vaccines or anti-viral
therapeutics that are effective against both non-ADE and ADE of
DENV infection. We provide experimental evidence that certain E
protein structures essential for virus entry during non-ADE DENV2
infection are also indispensable for ADE infection in FcγRII-bearing
K562 cells, and the entry pathway of DENV-Ab complexes in
FcγRIIA-mediated ADE may be similar to that of non-ADE DENV
infection. This report revealed that prevention measures targeted
to DENV entry and membrane fusion could potentially be effective
for both types of infection. It has been demonstrated that signaling
cascades following the binding between DENV–Ab complexes and
FcγR in myeloid cell lines trigger innate immune responses that
contribute to intrinsic ADE (Ubol et al., 2010.). However, signaling
cascades are only critical for FcγRIA-mediated DENV–Ab infection,
but not for FcγIIA-mediated ADE (Rodrigo et al., 2006). This study
only focused on investigating DENV2 E protein molecular deter-
minants involved in the extrinsic ADE mechanism, which is
predominantly mediated by FcγRIIA. Further studies to include
cells expressing FcγRIA (signaling competent or non-competent),
and cells expressing both FcγRIA and FcγRIIA will be necessary to
advance our understanding of ADE mechanisms of DENV infection.
Materials and methods
Cell cultures, viruses, and antibodies
The human myelogenous leukemia cell line K562, expressing
Fcγ receptor IIA (FcγRIIA) on cell surfaces (ATCC, CCL-243), was
cultured in Iscove's Modiﬁed Dulbecco's Medium (IMDM). Grivet
monkey kidney CV-1 cells stably transfected to express human
FcγRIIA (CD32), CV-1 CD32, provided by Dr. Jacob Schlesinger at
University of Rochester (Rodrigo et al., 2009), were cultured in
Dulbecco's Modiﬁed Eagle Medium (DMEM) containing 50 mg/mL
Hygromycin B (Roach). Both cell lines were cultured in medium
supplemented with 10% fetal bovine serum (FBS) and were incubated
at 37 1C with 5% CO2.
Viruses used in this study were recombinant DENV2 derived
from an infectious cDNA clone, pD2IC-30P-NBX, based on DENV2
strain 16681 (Huang et al., 2010; Kinney et al., 1997). The DENV2 E
mutants were previously engineered by site-directed mutagenesis
(Butrapet et al., 2011; Erb et al., 2010; Huang et al., 2010; Roehrig
et al., 2013). All viruses were recovered and passaged once in C6/
36 cells prior to infecting K562 cells.
A single batch of each unpuriﬁed mouse MAb, 4G2 (anti-
ﬂavivirus E protein), 1A1D-2 (anti-DENV-1, 2, and 3 E), 3H5
(anti-DENV2 E), and 2H2 (anti-DENV prM) prepared at CDC, DVBD,
Fort Collins, CO, was used in the study. MAb 2H2 used for staining
virus-infected cells for FACS was further puriﬁed and conjugated
with Alexa Fluor 488 using Alexa Fluors 488 protein labeling kit
(Invitrogen) following manufacturer's protocol, and used for
staining of de novo synthesized prM proteins within infected cells.
in vitro ADE assay
The in vitro ADE assay was conducted by infecting K562 or CV-1
CD32 cells with DENV2–Ab complexes in duplicate or triplicate.
Viruses at MOI of 0.01–1 (indicated in each experiment) were
incubated with MAbs to form DENV–Ab complexes at 37 1C (unless
otherwise speciﬁed) for 1 h prior to infection. The complexes were
incubated with equal volume of K562 cells in a total volume of
250 mL at 37 1C (unless otherwise speciﬁed) for 2 h adsorption.
Infected cells were washed twice with PBS to remove excess Ab
and virus, and cultured in 3 mL of medium with 5% FBS at 37 1C or
28 1C for 2–5 days, as speciﬁed in each experiment. The ADE assay
in CV-1 CD32 cells was performed in 6-well plates. Cells were
inoculated with 100 mL/well of virus–Ab complex for 2 h adsorp-
tion at 37 1C. After adsorption, cells were washed twice with
DMEM or PBS before culturing in 4 mL of DMEM with 5% FBS
and 50 mg/mL Hygromycin B.
ADE infection was compared side-by-side with infection by
DENV without Ab (non-ADE infection; virus was pre-incubated
with medium only). ADE and non-ADE infections with WT DENV2
30P-NBX were also included as the positive ADE control in each
experiment to validate the success of each ADE assay. Mock
infection was included as a negative control for each experiment
and used for standardizing experiments. On the days speciﬁed
in each experiment, culture medium and infected cells were
harvested for further viral RNA (vRNA) quantitation and cell infection
rate analysis, respectively.
Analysis of DENV infection rate
Infected cells were harvested and ﬁxed with 250 μL of BD
ﬁxation/permeabilization solution (BD Biosciences) at 4 1C for
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20 min. Fixed cells were washed twice with BD perm/wash buffer
and incubated with human FcR binding inhibitor (eBioscience) at
4 1C for 20 min to prevent binding of Fc of the 2H2 conjugate to
the FcR on the cell surface. Cells were than stained with 5.1 μg/mL
of 2H2-AlexaFluor-488 at a ﬁnal volume of 50 mL for 1 h at 37 1C.
The stained cells were washed and resuspended in 0.5–1.5 mL
of BD perm/wash buffer for FACSCalibur ﬂow cytometry analysis
(BD Biosciences). At least 20,000 events were acquired for each
sample, and the percent cell infection was analyzed by CellQuest
Pro software (BD Biosciences). The mock infection sample was
used to set gating parameters for each experiment so that the cell
auto-ﬂuorescence background was below 1%. Final percent cell
infection results were further normalized by subtracting the auto-
ﬂuorescence background. The non-ADE of WT DENV infection
baseline was used to carefully optimize infection procedure and
detection sensitivity/speciﬁcity of the FACS assay, so the non-ADE
infection baseline and the mock control background were sig-
niﬁcantly different.
Quantiﬁcation of viral RNA
All of the ADE assays measured by FACS were also conﬁrmed by
qRT-PCR of vRNA outputs. Viral RNA was extracted from infected
cell culture supernatant using the QIAamp viral RNA kit (Qiagen).
Viral genomic equivalents were analyzed on the CFX 96 TouchTM
Real-Time PCR Detection System (BioRad) by one-step qRT-PCR
with Quantitect virus kit (Qiagen), DENV2 primers, and TaqMan
DENV2 probe as previously described (Roehrig et al., 2013).
Quantitative RT-PCR cycling was performed as follows: RT at
50 1C, 20 min; 95 1C, 5 min for RT inactivation and hot start;
50 cycles of 95 1C, 15 s and 57 1C, 1 min 15 s. In vitro transcribed
vRNA from a DENV2 cDNA subclone was generated and quanti-
tated to make standard curves for each qRT-PCR assay as pre-
viously described (Butrapet et al., 2006). Each sample was
measured in 2 or 3 replicates.
Determination of FcγRIIA on cell surfaces
The expression of FcγRIIA (CD32) on the surfaces of K562 and
CV-1 CD32 cells was measured by FACSCalibur ﬂow cytometry.
Uninfected cells were ﬁxed in 100 μL of 4% paraformaldehyde at
4 1C for 20 min. Fixed cells were washed twice with PBS and 1%
FBS without permeabilization solution. The cells were stained with
mouse anti-human CD32 conjugated with phycoerythrin (PE)
(anti-CD32-PE Ab, eBioscience) for FcγRIIA staining, or with mouse
anti-IgG1 isotype control-PE Ab (eBioscience) for non-speciﬁc
binding control. The percent of cells expressing FcγRIIA was
calculated by subtracting the percent anti-IgG isotype control-
PE-staining background from the percent anti-CD32-PE for each
cell type. The GMFI was also measured to compare the FcγRIIA
expression levels between K562 and CV-1-CD32 cells. Histograms
of the anti-CD32-PE and the anti-IgG isotype control-PE from the
same cell type were overlaid, and GMFI of stained FcγRIIA for each
sample was calculated after subtracting the overlap curve of the
IgG isotype background control. All ﬁnal reported results were the
average from 3 separate experiments.
Statistics
Student's t-test was used to test for signiﬁcance and results
with po0.05 were considered signiﬁcant.
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